| Authors: |
Bijker EM; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Department of Paediatrics, Maastricht University Medical Centre, MosaKids Children's Hospital, Maastricht, the Netherlands., Smith JP; Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, USA; Department of Health Policy and Management, Yale University School of Public Health, New Haven, CT, USA., Mchembere W; Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya., McCarthy KD; U.S. Centers for Disease Control and Prevention, Kisumu, Kenya., Oord H; eNose B.V. (The eNose Company), Zutphen, the Netherlands., Gerritsen JW; eNose B.V. (The eNose Company), Zutphen, the Netherlands., Click ES; Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, USA., Cain K; Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, USA., Song R; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA. Electronic address: rinn.song@paediatrics.ox.ac.uk. |
